Lipegfilgrastim: pharmacodynamics and pharmacokinetics for body-weight-adjusted and 6 mg fixed doses in two randomized studies in healthy volunteers

References

• Holmes FA, O'Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002;20:727-31
   PubMed Web of Science ®Google Scholar
• Bennett CL, Djulbegovic B, Norris LB, Armitage JO. Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med 2013;368:1131-9
   PubMed Web of Science ®Google Scholar
• Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328-40
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011;52:e56-93
   PubMed Web of Science ®Google Scholar
• Holmes FA, Jones SE, O'Shaughnessy J, et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 2002;13:903-9
   PubMed Web of Science ®Google Scholar
• Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164-70
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Rabinowe SN, Singer JW, et al. Recombinant granulocyte–macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991;324:1773-8
   PubMed Web of Science ®Google Scholar
• Gulati SC, Bennett CL. Granulocyte–macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin disease. Ann Intern Med 1992;116:177-82
   PubMed Web of Science ®Google Scholar
• Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993;29A:319-24
   PubMed Web of Science ®Google Scholar
• Crawford J, Caserta C, Roila F. Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann Oncol 2010;21(Suppl 5):v248-51
   PubMed Web of Science ®Google Scholar
• Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-205
   PubMed Web of Science ®Google Scholar
• Neulasta [package insert]. Thousand Oaks, CA: Amgen Inc., 2014
   Google Scholar
• Yang BB, Kido A. Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clin Pharmacokinet 2011;50:295-306
   PubMed Web of Science ®Google Scholar
• Teva launches new biologicals in Europe and US. Generics and Biosimilars Initiative. Available at: http://www.gabionline.net/Biosimilars/News/Teva-launches-new-biologicals-in-Europe-and-US [Last accessed 19 May 2014]
   Google Scholar
• Assessment report: lonquex. European Medicines Agency. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002556/WC500148382.pdf [Last accessed 14 May 2014]
   Google Scholar
• Buchner A, Bias P, Kaufmann M. A randomized, double-blind, active control, multicenter, dose-finding study of XM22, glycopegfilgrastim, in patients with breast cancer receiving myelosuppressive therapy [abstract 9080]. J Clin Oncol 2011;29:9080
   Google Scholar
• Bondarenko I, Gladkov OA, Elaesser R, et al. Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy. BMC Cancer 2013;13:386-98
   PubMed Web of Science ®Google Scholar
• Gladkov OA, Volovat C, Bondarenko IM, et al. Efficacy and safety of lipegfilgrastim in patients with lung cancer who are receiving chemotherapy [abstract 1014]. Support Care Cancer 2012;20:S243
   Google Scholar
• Molineux G. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharm Des 2004;10:1235-44
   PubMed Web of Science ®Google Scholar
• Mueller U, Kohler E, Bias P, et al. Glyco-PEGylated R-metHuG-CSF (XM22/lipegfilgrastim) – a novel long-acting once-per-cycle filgrastim: pharmacokinetics and pharmacodynamics for body weight adjusted doses and a 6 mg fixed dose in health volunteers [abstract 1215]. Eur J Cancer 2011;47(Suppl 1):S149
   Google Scholar
• Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:29-35
   PubMed Web of Science ®Google Scholar
• Sutherland DR, Anderson L, Keeney M, et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996;5:213-26
   PubMedGoogle Scholar
• Guideline on clinical trials with haematopoietic growth factors for the prophylaxis of infection following myelosuppressive or myeloablative therapy (EMEA/CPMP/555/95 Rev. 1). European Medicine Agency. Available at: www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/12/WC500017738.pdf [Last accessed 15 October 2013]
   Google Scholar
• Kroschinsky F, Holig K, Poppe-Thiede K, et al. Single-dose pegfilgrastim for the mobilization of allogeneic CD34+ peripheral blood progenitor cells in healthy family and unrelated donors. Haematologica 2005;90:1665-71
   PubMed Web of Science ®Google Scholar
• Molineux G, Kinstler O, Briddell B, et al. A new form of filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 1999;27:1724-34
   PubMed Web of Science ®Google Scholar
• El-Ouriaghli F, Sloand E, Mainwaring L, et al. Clonal dominance of chronic myelogenous leukemia is associated with diminished sensitivity to the antiproliferative effects of neutrophil elastase. Blood 2003;102:3786-92
   PubMed Web of Science ®Google Scholar
• Abdolzade-Bavil A, Cooksey BA, Scheckermann C, et al. Pegylated versus glycopegylated G-CSFs and their biochemical and physiological properties [abstract]. Blood 2013;122:4851
   Web of Science ®Google Scholar
• Volovat C, Bondarenko IM, Gladkov OA, et al. Efficacy and safety of lipegfilgrastim compared with placebo in elderly patients with non-small cell lung cancer receiving cisplatin/etoposide chemotherapy [poster]. Presented at the Annual Meeting of the International Society of Geriatric Oncology, Manchester, UK, 25–27 October 2012
   Google Scholar
• Bennett CL, Evens AM, Andritsos LA, et al. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol 2006;135:642-50
   PubMed Web of Science ®Google Scholar
• Dincer AP, Gottschall J, Margolis DA. Splenic rupture in a parental donor undergoing peripheral blood progenitor cell mobilization. J Pediatr Hematol Oncol 2004;26:761-3
   PubMed Web of Science ®Google Scholar